Grab your piece of “AI” STOCK winnings with an AI PhD expert

As an equity market strategist with a Ph.D. in AI/pattern-recognition and over four decades as a very successful Portfolio Manager, I know we are on the verge of a revolution for business and daily life driven by artificial intelligence. Subscribers to our A.I. Stock Tips serviceswill receive specific guidance in advance, as to which stocks still have potential for tremendous growth.

As Andy Jassy, CEO of AMAZON, wrote recently:

"Generative AI may be the largest technology transformation since the cloud (which itself, is still in the early stages), and perhaps since the Internet. This GenAI revolution will be built from the start on top of the cloud. The amount of societal and business benefit from the solutions that will be possible, will astound us all"

The massive investment in AI over the past couple of years has mainly been in hardware and firmware (chips) and NVDA positioned itself to exploit the opportunity, and has been richly rewarded by about a 300% pop in its share price over 12 months.

AMD has now largely caught up with it in technology, but there is still room for BOTH to grow their profits rapidly. However, both stock price VALUATIONS are extremely high relative to their earnings per share. Alternatives with lower EPS, whose potential we like include GOOG, MSFT, APPL, IBM, C3.AI, and APPN.

The Market is expecting MSFT to have greater rapid growth ahead, compared with GOOG (Alphabet), because of MSFT’s partnership with OpenAi to build a $100-billion Stargate AI supercomputer by 2028. However, we believe GOOG has the potential to overtake MSFT over the next couple of years because of GOOG’s greater depth in AI technology, as well as “side bets” like Waymo (Robotaxis) becoming fully commercialized.

Unfortunately, the major players have not yet offered personalized agents to make chat-bot responses more relevant to individual consumers and thus made the user more responsible for the subsequent chat-bot responses. The tech giants have also remained largely captive to a mathematical approach to the architecture of AI algorithms, unwilling or unable to factor in unavoidable psychological, emotional, and political aspects of condensing and synthesizing knowledge. We believe this situation presents large possibilities for the savvy investor to take long and short positions; based on judgements of how various companies in the AI space are altering their approaches to their design of AI algorithms and the marketing of resulting end-user products.

Highlights of the First Webinar to PRO subscribers

[ planned for June 2, 2024: 6 pm Pacific Time ]

[ This is just an EXAMPLE, based on Stock Market conditions on 4/15/24; it will be updated by 5/31/24 for Market conditions at that time ]

  • Beamr Imaging (BMR) has a moat for sustainable rapid growth
  • ServiceNow (NOW) has shown impeccable execution of its AI strategy
  • SNOW's valuation cannot be defended for long
  • AI stocks expected to move significantly TOMORROW

SUBSCRIBE NOW promotions

The PRO version described above will offer webinars prior to each trading DAY. [ trading/investment horizon: 3 to 24 months ]
$4.90 per mo. (which is a 50% discount)


You may also subscribe now to the BASIC version, which will offer webinars prior to each trading WEEK [ trading/investment horizon: 3 to 24 months ]

99cents per mo. (locked-in rate for 6 months)
Full description of BASIC_AIstockTIPS

For either or both  Subscriptions

The number of Members accepted at this introductory stage will be limited; so please apply early. You may cancel anytime before 3 days prior to any Webinar; and be refunded for the balance of any events you will not be attending. 

------------------  BIO of Webinar Host, Dr. Sean Subas, PhD -----------------

Dr. Sean Subas has more than four decades of experience as a senior executive, consultant, and entrepreneur with a wide variety of organizations. He received an M.S. in physics and his Ph.D. in electrical engineering and computer science from Purdue University, where he was a Fulbright Scholar, before earning his M.B.A. at the University of California at Berkeley in 1982. He has authored 11 articles in academic publications and received national awards for innovation, business development, and teamwork.

From 1982 to 1990, Dr. Subas served as executive vice president at the Liquidity Financial Group, where he directed a 30-person team as a licensed financial principal evaluating securities, as Portfolio Manager, for a series of Investor [mutual] Funds. In 1991 he founded Business-Aid, Inc., a consultancy in the high tech and financial sectors, providing services ranging from software application development to raising venture capital for startups in Silicon Valley.

From 1994 to 1998, Dr. Subas was a managing director/Portfolio Manager at CB Richard Ellis, creating and implementing computer systems to analyze the operations and finances of over 100 companies on a quarterly basis. He then served as executive vice president at Invenex 1999-2002, where he developed the first online trading of timeshare intervals and led a large team enabling the U.S. Department of Defense to capture and transmit ultrasound cardiograms for veterans.

From 2002 to 2004, at the US Department of Defense, Edwards Air Force Base; Dr. Subas managed all training initiatives at the Acquisition Center of Excellence, was mission-area manager to the IT Directorate, and a contract negotiator on several acquisitions. He then became a business development specialist for the U.S. Department of Commerce 2004-12, helping companies grow rapidly.

Dr. Subas founded in 2013, where he continues to provide integrative-health plans for a wide range of health issues, incorporating everything from Meditation and traditional Chinese medicine to Western functional medicine and Yoga. Dr. Subas is a certified Health Coach.


Information and statements regarding dietary supplements, or any other healthcare protocol, provided herein; have not been evaluated by the Food and Drug Administration in the USA, or any similar Agency in another country, and are not intended to diagnose, treat, or cure any disease. OASISforHEALTH assumes no liability for inaccuracies or misstatements.
Copyright notice
Text is made available under the Creative Commons Attribution-ShareAlike License
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the licensor, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.


To Make comments, please subscribe to facebook page, by same title